AMRI will close its DDS facility in Syracuse, NY.
AMRI
reported that it will be transitioning Discovery and Development Services (DDS) activities at its Syracuse, NY site to other sites within AMRI and will terminate all operations in Syracuse by the end of June 2014.
As part of the transition, Syracuse DDS capabilities and some employees will be transferred to other AMRI facilities, including Albany, NY; Cedarburg, Wis.; Holywell, UK; and Hyderabad, India. AMRI expects the closure will generate annual run-rate savings of approximately $1.5 million.
Source:
AMRI
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.